COX-2 inhibitors top 20 mil. scripts
Pfizer/Searle's Celebrex ended 1999 with a total of 16.6 mil. prescriptions following a January 1999 launch, while Merck's Vioxx had 4.6 mil. prescriptions for the year after its May launch, according to IMS Health data
You may also be interested in...
Switches from Celebrex to Vioxx accounted for approximately 7% of prescriptions for Merck's COX-2 inhibitor during November.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011